BR112017016934A2 - [9,10-dimetóxi-3-(2-metilpropil)- 1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il] metanol e compostos, composições e métodos relacionados ao mesmo - Google Patents

[9,10-dimetóxi-3-(2-metilpropil)- 1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il] metanol e compostos, composições e métodos relacionados ao mesmo

Info

Publication number
BR112017016934A2
BR112017016934A2 BR112017016934-7A BR112017016934A BR112017016934A2 BR 112017016934 A2 BR112017016934 A2 BR 112017016934A2 BR 112017016934 A BR112017016934 A BR 112017016934A BR 112017016934 A2 BR112017016934 A2 BR 112017016934A2
Authority
BR
Brazil
Prior art keywords
compounds
methods related
compositions
metilpropil
dimetóxi
Prior art date
Application number
BR112017016934-7A
Other languages
English (en)
Other versions
BR112017016934B1 (pt
Inventor
Ashweek Neil
Harriott Nicole
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of BR112017016934A2 publication Critical patent/BR112017016934A2/pt
Publication of BR112017016934B1 publication Critical patent/BR112017016934B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

são revelados compostos com uma estrutura de fórmula (i), incluindo este-reoisômeros e sais e solvatos farmaceuticamente aceitáveis dos mesmos: (i) onde r1 é conforme definido acima. esses compostos são inibidores do transportador vesicular de monoamina 2 (vmat2) e são úteis no tratamento, por exemplo, de transtornos hipercinéticos. também são reveladas composições que contêm esses compostos em combinação a um veículo ou diluente farmaceutica-mente aceitável, bem como métodos relacionados ao uso em um paciente que delas necessite.
BR112017016934-7A 2015-02-06 2016-02-05 Compostos inibidores do transportador vesicular de monoamina 2 (vmat2), composição farmacêutica compreendendo os mesmos, uso dos mesmos para tratar um transtorno hipercinético, esquizofrenia e transtorno bipolar e método para preparar a dita composição farmacêutica BR112017016934B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113316P 2015-02-06 2015-02-06
US62/113,316 2015-02-06
PCT/US2016/016892 WO2016127133A1 (en) 2015-02-06 2016-02-05 [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Publications (2)

Publication Number Publication Date
BR112017016934A2 true BR112017016934A2 (pt) 2018-04-03
BR112017016934B1 BR112017016934B1 (pt) 2023-09-12

Family

ID=

Also Published As

Publication number Publication date
EP3253752A1 (en) 2017-12-13
EP3253752B1 (en) 2023-08-16
US11053242B2 (en) 2021-07-06
CN107438606A (zh) 2017-12-05
NZ733899A (en) 2024-01-26
RU2017130514A (ru) 2019-03-07
MX2017010062A (es) 2017-11-01
EP3253752C0 (en) 2023-08-16
AU2016215033A1 (en) 2017-08-10
JP2018504437A (ja) 2018-02-15
US9988382B2 (en) 2018-06-05
US20180273533A1 (en) 2018-09-27
KR20170113620A (ko) 2017-10-12
IL253704A0 (en) 2017-09-28
RU2736509C2 (ru) 2020-11-17
US20170349586A1 (en) 2017-12-07
WO2016127133A1 (en) 2016-08-11
KR102586138B1 (ko) 2023-10-05
AU2016215033B2 (en) 2020-06-25
IL253704B (en) 2021-02-28
RU2017130514A3 (pt) 2019-08-27
CA2974540A1 (en) 2016-08-11
JP6755254B2 (ja) 2020-09-16
US9714246B2 (en) 2017-07-25
CA2974540C (en) 2023-09-26
CN107438606B (zh) 2020-09-18
US20200262834A1 (en) 2020-08-20
US20160289226A1 (en) 2016-10-06
ES2960717T3 (es) 2024-03-06

Similar Documents

Publication Publication Date Title
MX2017010062A (es) [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
AR081628A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
BR112015022483A2 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
MX2020001832A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
PH12015502159A1 (en) Chemical entities
EA201690127A1 (ru) Состав на основе ингибиторов syk
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
AR104174A1 (es) Oxadiazoles sustituidos con deuterio
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
NZ748769A (en) Nitroxyl donors with improved therapeutic index
BR112016026046A8 (pt) uso de compostos de tienotriazolodiazepina
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
BR112017008794A2 (pt) inibidores de di-heteroaril histona desacetilase e seu uso em terapia
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
PH12019501566A1 (en) Amide compounds and use thereof
BR112014031969A2 (pt) derivados de pirimidinona como agentes antimaláricos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 455/04

Ipc: C07D 455/04 (2006.01), C07D 471/04 (2006.01), C07D

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2016, OBSERVADAS AS CONDICOES LEGAIS